Pro-inflammatory cytokines and downstream pathways

Pro-inflammatory cytokines are a diverse group of signaling proteins, including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), that are primarily produced by activated macrophages and helper T cells to mediate and regulate immunity and inflammation (StatPearls, 2023). These molecules bind to specific cell-surface receptors, triggering downstream signaling cascades such as the Janus kinase/signal transducer and activator of transcription (JAK/STAT), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and mitogen-activated protein kinase (MAPK) pathways (Nature Reviews Drug Discovery, 2017). While these pathways are essential for host defense, their chronic dysregulation is a hallmark of numerous inflammatory and autoimmune conditions, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis (PubMed, PMID: 30272097). Therapeutic intervention often involves monoclonal antibodies that neutralize the cytokines themselves or small molecules that inhibit the intracellular kinases responsible for signal transduction (NIH, 2022). While highly effective in reducing systemic inflammation, targeting these pathways can lead to significant safety concerns, most notably an increased susceptibility to opportunistic infections and potential long-term risks of malignancy due to suppressed immune surveillance (Frontiers in Immunology, 2021). Clinical monitoring of treatment efficacy typically involves the assessment of systemic biomarkers such as C-reactive protein and specific cytokine concentrations.

Other names

Pro-inflammatory cytokine signalingInflammatory cytokine pathwaysCytokine-mediated signaling cascades

Therapeutic strategies involve the neutralization of circulating cytokine ligands, competitive antagonism of cell-surface cytokine receptors, or the inhibition of intracellular signaling enzymes such as Janus kinases (JAKs) to prevent the transcription of pro-inflammatory genes (PubChem, 2024; NIH, 2022).